Methods of modulating matrix metalloproteinase activity and uses thereof
Patent 6403637 Issued on June 11, 2002. Estimated Expiration Date: August 9, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
Methods for inactivating matrix metalloproteinases in a vertebrate cell are disclosed. The methods comprise administering to the cell an agent which causes increased endocytosis of the matrix metalloproteinase. Methods for treating vertebrates with disorders mediated by matrix metalloproteinases are also disclosed. These methods comprise administering the above-described agents to the vertebrate. Also disclosed is the use of HMG-CoA reductase inhibitors, also known as statins, as an agent which causes increased endocytosis of matrix metalloproteinases. Assays for determining whether an agent is effective in treating a disorder are also disclosed. These assays comprise testing the agent for activity in increasing endocytosis of a matrix metalloproteinase which mediates the disorder.
Other References
Bonapace, Ian et al.; "17Beta-Estradiol . . . -2 MAP kinases activation."; Oncogene; vol. 12; pp. 753-763, 1996.
Andreasen et al., Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes, FEBS Lett. 338:239 (1994)
Brown et al., Recycling Receptors: The Round-Trip Itinerary of Migrant Membrane Proteins, Cell 32:663-667 (1983)
Brown et al., Calcium cages, acid baths and recycling receptors, Nature 388:629-630 (1997)
Brown et al., Receptor-mediated endocytosis: Insights from the lipoprotein receptor system, Proc. Natl. Acad. Sci. USA 76:3330-3337 (1979)
Conese et al., -2 Macroglobulin Receptor/Ld1 Receptor-related Protein (Lrp)-dependent Internalization of the Urokinase Receptor, J. Cell Bio. 131:1609-1622 (1995)
Cs-Szabo et al., Changes in Messenger RNA and Protein Levels of Proteoglycans and Link Protein in Human Osteoarthritic Cartilage Samples, Arthritis and Rheumatism 40:1037-1045 (1997)
Cui et al., Lovastatin Prevents Steroid Induced Adipogenesis and Osteonecrosis, Clin. Ortho. Related Res. 344:8-19 (1997)
Durr et al., Localization of 댡-Integrins in Human Cartilage and Their Role in Chondrocyte Adhesion to Collagen and Fibronectin, Exper. Cell Res. 207:235-244 (1993)
Ellgaard et al., Dissection of the domain architecture of the 2 macroglobulin-receptor-associated protein, FEBS Lett. 244:544-551 (1997)
Fisher et al., Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, PNAS 96:133-138 (1999)
Freije et al., Molecular Cloning and Expression of Collagenase-3, a Novel Human Matrix Metalloproteinase Produced by Breast Carcinomas, J. Biol. Chem. 269:16766-16773 (1994)
Herz et al., Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor, EMBO J. 7:4119-4127 (1988)
Hollander et al., Damage to Type II Collagen in Aging and Osteoarthritis Starts at the Articular Surface, Originates Around Chondrocytes, and Extends into the Cartilage with Progressive Degeneration, J. Clin. Invest. 96:2859-2869 (1995)
Huhtala et al., Cooperative Signaling by 댕댡 and 댔댡 Integrins Regulates Metalloproteinase Gene Expression in Fibroblasts Adhering to Fibronectin, J. Cell. Biol. 129:867-879 (1995)
Irvine et al., Evidence of Collagenase-3 Receptor Dysfunction in Osteoarthritic Cartilage, 2nd Symposium International Cartilage Repair Society, (Nov. 16, 1998)
Kounnas et al., Cellular Internalization and Degradation of Antithrombin III-Thrombin, Heparin Cofactor II-Thrombin, and 1 -Antitrypsin-Trypsin Complexes Is Mediated by the Low Density Lipoprotein Receptor-related Protein, J. Biol. Chem. 271:6523-6529 (1996)
Kozaci et al., Degradation of Type II Collagen, but not Proteoglycan, Correlates with Matrix Metalloproteinase Activity in Cartilage Explant Cultures, Arth. Rheumatism 40:164-174 (1997)
Krane et al., Different Collagenase Gene Products Have Different Roles in Degradation of Type I Collagen, J. Biol. Chem. 271:28509-28515 (1996)
Lapadula et al., Integrin expression on chondrocytes: Correlations with the degree of cartilage damage in human osteoarthritis, Clin. Exper. Rheumatol. 15:247-254 (1998)
Lohmander et al., Defining the Role of Molecular Markers to Monitor Disease, Intervention, and Cartilage Breakdown in Isteoarthritis, J. Rheumatol. 24:782-785 (1997)
Lovejoy et al., Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors, Nature Struct. Biol. 6:217-221 (1999)
Mundy et al., Identification of a New Class of Powerful Stimulators of New Bone Formation in Vivo, Clarification of Mechanism of Action, and use in Animal Models of Osteoporosis, Bone 23:S183 (Abstract-1144) (1998)
Nielson et al., Identification of Residues in -Macroglobulins Important for Binding to the 2 -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein, J. Biol. Chem. 271:12909-12912 (1996)
Nykjaer et al., Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes, EMBO J. 16:2610-2620 (1997)
Nykjaer et al., Regions Involved in Binding of Urokinase-Type-1 Inhibitor Complex and Pro-urokinase to the Endocytic 2 -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein, J. Biol. Chem. 269:25668-25676 (1994)
Omura et al., Identification of a Specific Receptor for Interstitial Collagenase on Osteoblastic Cells, J. Biol. Chem. 269:24944-24998 (1994)
Partridge et al., The Regulation and Regulatory Role of Collagenase in Bone, Crit. Rev. Eukar. Gene Expression 6:15-27 (1996)
Partridge et al., Hormonal Regulation of the Production of Collagenase and a Collagenase Inhibitor Activity by Rat Osteogenic Sarcoma Cells, Endocrinology 120:1956-1962 (1987)
Reboul et al., The New Collagenase, Collagenase-3, Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes, J. Clin. Invest. 97:2011-2019 (1996)
Roswit et al., Purification and Properties of Rat Uterine Procollagenase, Arch. Biochem. Biophys. 225:285-295 (1983)
Shingleton et al., Collagenase: a key enzyme in collagen turnover, Biochem. Cell Biol. 74:;759-775 (1996)
Sottrup-Jensen et al., Domain structure of human 2 -macroglobulin, FEBS Lett. 205:20-24 (1986)
Walling et al., Regulation of the Collagenase-3 Receptor and its Role in Intracellular Ligand Trafficking in Rat Osteoblastic Cells, Archives of Pharmacology (1998) (Abstract-P 57.32)
Walling et al., Characterization of Collagenase-3 Ligand-Receptor Interaction in Ostoblastic Cells, Bone 23:S326 (Abstract-W029) (1998)
Walling et al., Regulation of the Collagenase-3 Receptor and Its Role in Intracellular Ligand Processing in Rat Osteoblastic Cells, J. Cellular Physiol. 177:563-574 (1998)
Walling et al., Reduced Activity of the Collagenase-3 Receptor in Human Osteoarthritic Tissues, Research Poster Finalist #19, SCP-ASIM Medical Student Competition (Apr. 24, 1999)
Warshawsky et al., Identification of Domains on the 39-kDa Protein That Inhibit the Binding of Ligands to the Low Density Lipoprotein Receptor-related Protein, J. Biol. Chem. 268:22046-22054 (1993)
Wolfe et al., Differential In Vivo Expression of Collagenase Messenger RNA in Synovium and Cartilage, Arthritis Rhum. 36:1540-1547 (1993)
Wu et al., Characterization of a Novel Member of the Macrophage Mannose Receptor Type C Lectin Family, J. Biol. Chem. 271:21323-21330 (1996)
Zheng et al., Organ Distribution in Rats of Two Members of the Low-density Lipoprotein Receptor Gene Family, Gp330 and LRP/MR, and the Receptor-associated protein (RAP), J. Histochem. Cytochem. 42:531-542 (1994)
Zlabinger et al., Change in collagen synthesis of human chondrocyte culture, Rheumatol. Int. 6:63-68 (1986
August 9, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
